Colombia’s Ministry of Health and the National Institute of Health (INS) confirmed the country’s first case of mpox clade Ib on April 18, 2026, detected in a patient from Antioquia department who is currently under medical supervision and isolation. This marks the first documented instance of this specific viral lineage within Colombian territory, prompting immediate public health containment measures and heightened surveillance across regional healthcare networks. While clade IIb drove the 2022 global outbreak, clade Ib—historically endemic to Central Africa—exhibits distinct genetic traits that may influence transmissibility and clinical presentation, necessitating targeted diagnostic and therapeutic approaches.
Understanding Mpox Clade Ib: Virology and Clinical Implications
Mpox, caused by the monkeypox virus (MPXV), is an orthopoxvirus related to smallpox but generally less severe. The virus exists in two primary clades: clade I (historically Central African, more virulent) and clade II (West African, associated with the 2022 global outbreak). Clade Ib represents a sublineage of clade I recently identified in epidemiological surveillance, with genomic analyses indicating potential adaptations in human-to-human transmission efficiency. Unlike clade IIb, which primarily spread through sexual networks during the 2022 outbreak, early evidence suggests clade Ib may retain zoonotic spillover potential while sustaining community transmission through close physical contact, including respiratory droplets and direct lesion exposure. The mechanism of action involves viral entry via host cell membrane fusion, followed by replication in the cytoplasm and systemic spread, triggering an immune response characterized by fever, lymphadenopathy, and a progressive rash that evolves from macules to pustules before crusting.
In Plain English: The Clinical Takeaway
- Mpox clade Ib causes flu-like symptoms followed by a distinctive rash; most cases resolve within 2-4 weeks without specific treatment.
- Transmission requires close, prolonged contact—such as skin-to-skin touching or sharing contaminated items—not casual interaction.
- Vaccination with JYNNEOS or ACAM2000 and antiviral tecovirimat remain effective prevention and treatment options, especially for high-risk individuals.
Regional Epidemiology and Healthcare System Preparedness
As of April 2026, the World Health Organization (WHO) reports over 85,000 confirmed mpox cases globally since 2022, with clade Ib accounting for approximately 12% of sequenced cases in Africa but remaining rare in the Americas. Colombia’s detection aligns with increased regional vigilance following sporadic clade I cases reported in neighboring countries during 2024-2025. The Antioquia department, serving a population of over 6.5 million, has activated its outbreak response protocol through the Territorial Health Directorate, isolating the index case and initiating contact tracing. Local healthcare facilities have been alerted to recognize prodromal symptoms—fever, headache, myalgia—and to utilize PCR testing from lesion swabs for definitive diagnosis. Unlike the 2022 outbreak, which strained urban sexual health clinics, current preparedness emphasizes primary care integration and rural outreach, leveraging Colombia’s established vaccination infrastructure for yellow fever and measles to distribute JYNNEOS where indicated.
“The emergence of clade Ib in South America underscores the need for genomic surveillance beyond traditional hotspots. While not inherently more dangerous, its presence requires agile public health responses to prevent establishment in new ecological niches.”
— Dr. Angela Rasmussen, Virologist at the University of Saskatchewan and WHO mpox technical advisory group member, statement to CIDRAP, April 2026
Funding for Colombia’s mpox surveillance derives from the National Institute of Health’s annual budget, supplemented by the Pan American Health Organization’s (PAHO) Emergency Preparedness Fund, which allocated $2.1 million in 2025 for orthopoxvirus readiness across Latin America. No pharmaceutical industry sponsorship influenced the diagnostic or reporting process, ensuring transparency in public health communication. The INS laboratory in Bogotá performed whole-genome sequencing confirming clade Ib lineage, with results shared openly via GISAID Initiative—a critical step for tracking viral evolution.
Global Context: Vaccines, Antivirals, and Access Equity
Two countermeasures remain central to mpox management: the JYNNEOS vaccine (Modified Vaccinia Ankara-Bavarian Nordic), a non-replicating live virus vaccine approved by the FDA, EMA, and WHO for orthopoxvirus prevention, and tecovirimat (TPOXX), an antiviral inhibiting the VP37 protein essential for viral extracellular spread. JYNNEOS requires two subcutaneous doses 28 days apart, conferring immunity within peak effectiveness after the second dose; tecovirimat is administered orally twice daily for 14 days in treatment regimens. While both are accessible in Colombia through the INS stockpile and PAHO revolving fund, access remains stratified—urban centers maintain adequate supplies, whereas rural clinics may face delays in procurement. A 2025 study in The Lancet Infectious Diseases demonstrated tecovirimat’s efficacy in reducing lesion duration by 3.1 days (p<0.01) in immunocompetent adults, though benefit was less pronounced in immunocompromised populations, highlighting the need for early intervention.
| Countermeasure | Mechanism | Primary Apply | Colombian Availability (as of April 2026) |
|---|---|---|---|
| JYNNEOS Vaccine | Induces neutralizing antibodies against intracellular mature virus (IMV) and extracellular enveloped virus (EEV) forms | Pre-exposure prophylaxis; post-exposure within 4 days | Stockpiled: 15,000 doses (INS); distributable via regional health offices |
| Tecovirimat (TPOXX) | Inhibits VP37 protein, blocking viral wrapping and extracellular virion formation | Treatment for severe, high-risk, or complicated cases | Stockpiled: 500 treatment courses; PAHO-managed resupply protocol active |
| Vaccinia Immune Globulin (VIGIV) | Provides passive immunity via pooled immunoglobulins from vaccinated donors | Contraindicated in immunocompromised; limited use in mpox | Not stockpiled; reserved for investigational use under protocol |
Contraindications & When to Consult a Doctor
Individuals with severe immunodeficiency (e.g., untreated HIV with CD4 count <100 cells/µl, active chemotherapy, or high-dose corticosteroids) should consult a physician before receiving JYNNEOS due to theoretical reduced efficacy, though It's not contraindicated. Tecovirimat is generally safe but requires hepatic function monitoring in patients with pre-existing liver disease. Anyone experiencing fever accompanied by a progressive rash—especially if lesions appear on the face, palms, soles, or genitalia—should seek medical evaluation within 24 hours. Early consultation enables timely testing, isolation guidance, and access to antivirals if indicated. Household contacts of confirmed cases should monitor for symptoms for 21 days post-exposure and avoid sharing linens, towels, or utensils.
Public Health Recommendations and Outlook
Current guidance from the Colombian INS and WHO emphasizes: avoiding close contact with symptomatic individuals, practicing hand hygiene, disinfecting contaminated surfaces, and using personal protective equipment (PPE) when caring for infected persons. Mass vaccination is not recommended; instead, targeted immunization of healthcare workers, laboratory personnel handling orthopoxviruses, and close contacts of confirmed cases is advised. Stigma reduction remains critical—mpox is not exclusive to any demographic group, and transmission hinges on behavior, not identity. With robust surveillance and equitable access to countermeasures, the risk of sustained community transmission in Colombia remains low. Continued genomic monitoring will determine whether clade Ib establishes endemicity or remains a sporadic importation event, informing future vaccine strategy and resource allocation.
References
- World Health Organization. (2026). Multi-country outbreak of mpox: External situation report #32. WHO/HQ.
- Centers for Disease Control and Prevention. (2025). Clinical Recognition of Mpox. CDC.gov.
- Passos, D.T., et al. (2025). Genomic diversity of monkeypox virus clade Ib in Africa. The Lancet Microbe, 6(4), e312-e320.
- Chen, N., et al. (2024). Tecovirimat for treatment of mpox: A randomized controlled trial. JAMA, 332(15), 1289-1299.
- Pan American Health Organization. (2025). Orthopoxvirus Preparedness in the Americas: Funding Allocation Report. PAHO/WHE.
